Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Hansenula-Derived Pegylated-Interferon Alpha-2a and Ribavirin Customized Combination Therapy in Egyptian Children With Chronic Hepatitis C Infection

NCT02027493 is registered in ClinicalTrials.gov with National Liver Institute, Egypt as lead sponsor.

NCT NCT02027493
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02027493 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Hansenula-Derived Pegylated-Interferon Alpha-2a and Ribavirin Customized Combination Therapy in Egyptian Children With Chronic Hepatitis C Infection
Lead sponsor
National Liver Institute, Egypt
Phase
Not applicable
Overall status
Completed
Start date
February 28, 2009
Completion date
August 31, 2011
Enrollment
46 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c, chronic